HLA
AGRX

Hamilton Lane Advisors’s Agile Therapeutics AGRX Stock Holding History

Hamilton Lane Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-27
Closed -$308K – 72
2016
Q4 		$308K Sell
27
-1
-4% -$14K 0.2% 52
2016
Q3 		$387K Buy
+28
New +$400K 0.19% 50

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Hamilton Lane Advisors's AGRX Position: Q1 2017 in Review

Hamilton Lane Advisors sold out of Agile Therapeutics (AGRX) in Q1 2017, closing a stake of 27 shares — an estimated $308K sold.

Hamilton Lane Advisors first reported a position in AGRX in Q3 2016 and held it in 2 quarters. The position peaked at $387K in Q3 2016. 48 funds tracked by Wall St. Rank hold AGRX as of Q1 2017.

  • Hamilton Lane Advisors reported no remaining Agile Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Hamilton Lane Advisors sold 27 Agile Therapeutics shares in Q1 2017, an estimated $308K.
  • Hamilton Lane Advisors first reported a position in Agile Therapeutics in Q3 2016 and held it in 2 quarters.
  • Hamilton Lane Advisors's Agile Therapeutics position peaked at $387K in Q3 2016.
  • 48 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2017.

Based on Hamilton Lane Advisors's 13F filing for Q1 2017, filed 24 Apr 2017.